BioMendics Brings New Hope for Epidermolysis Bullosa Simplex Patients as TAMES‑02 Trial ...

BioMendics advances its TAMES-02 trial of TolaSure™, a potential disease-modifying topical therapy for Epidermolysis Bullosa ...